The PennZone

  • Home
  • Health
  • Non-profit
  • Business
  • Technology
  • Services
  • Travel
  • Construction
  • Sports

Utah attempts to legalize placenta cell therapy
The PennZone/10266985

Trending...
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
  • Beycome Closes $2.5M Seed Round Led by InsurTech Fund
Parent's Guide to Cord Blood Foundation
Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

BROOKEVILLE, Md. - PennZone -- Exclusive: How a small group of patient advocates and biotech companies tricked the Utah legislature into passing a law which sets a precedent. Utah is now the first state to legalize therapy with stem cells from placenta tissue and cord blood.

Parent's Guide to Cord Blood Foundation is a small non-profit in the biotech space. We are the first to break the story that the Utah state legislature did not realize what they were voting for when they passed Utah S.B. 199.

More on The PennZone
  • Trump's Executive Order Rescheduling Cannabis: Accelerating M&A in a Multibillion-Dollar Industry
  • Genuine Hospitality, LLC Selected to Operate Hilton Garden Inn Birmingham SE / Liberty Park
  • Together We Dance Foundation Announces Transformational Support from NAC Have a Heart Foundation
  • Harry Hayman Celebrates Years of WHYY Coverage, Partnership & Shared Commitment to Philadelphia
  • Documentary "Prescription for Violence: Psychiatry's Deadly Side Effects" Premieres, Exposes Link Between Psychiatric Drugs and Acts of Mass Violence

The FDA still considers unapproved stem cell therapies to be illegal, and when it comes to drug regulations, federal law takes supremacy. This is not the same as states ignoring federal law and legalizing recreational drugs. In the case of stem cell therapy, patients that receive unregulated products with insufficient oversight could suffer serious adverse events. The new law Utah S.B. 199 is going to trigger a showdown between the federal government and Utah. Doctors who administer therapy to patients under the new Utah law could be sued by the Dept. of Justice. At a bare minimum, we are calling for the state of Utah to establish oversight of this arena before patients are hurt.

Contact
Frances Verter, PhD
***@parentsguidecordblood.org


Source: Parent's Guide to Cord Blood Foundation

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Schmuck Lumber Ace Hardware Opens New Greenhouse Addition
  • Renowned Alternative Medicine Specialist Dr. Sebi and His African Bio Mineral Balance Therapy Are the Focus of New Book
  • Psychiatric Drug Damage Ignored for Decades; CCHR Demands Federal Action
  • Why Millions Are Losing Sexual Sensation, And Why It's Not Age, Hormones, or Desire
  • Justin Jeansonne An Emerging Country Singer-Songwriter Music Fans Have Been Waiting For…a True Maverick
  • Russellville Huntington Learning Center Expands Access to Literacy Support; Approved Provider Under Arkansas Department of Education
  • UK Financial Ltd Launches U.S. Operations Following Delaware Approval
  • Pinealage: the app that turns strangers into meditation companions — in crowdfunding phase
  • Top Tips for Hiring HVAC Contractors in Philadelphia
  • Harry Hayman of Feed Philly Coalition Proudly Supports Sharing Excess' Holiday Food Rescue — Bri
  • Virtual Pizza Academy Announces the Return of Two Acclaimed Live Classes in 2026:
  • Teresa James & The Rhythm Tramps announce their new album and debut on MoMojo Records, 'Bad at Being Good'
  • "Micro-Studio": Why San Diegans are Swapping Crowded Gyms for Private, One-on-One Training at Sweat Society
  • Beycome Closes $2.5M Seed Round Led by InsurTech Fund
  • VIP Vacations Invited to Travel Weekly's Annual Readers Choice Awards
  • Tru by Hilton Columbia South Opens to Guests
  • Christy Sports donates $56K in new gear to SOS Outreach to help kids hit the slopes
  • "BigPirate" Sets Sail: A New Narrative-Driven Social Casino Adventure
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Women's Everyday Safety Is Changing - The Blue Luna Shows How

Popular on PennZone

  • Liquidity Aggregation: US-Registered JHKXWL Integrates AI Analytics for Brazilian and Global Institutional Traders - 1213
  • UK Financial Ltd Board of Directors Establishes Official News Distribution Framework and Issues Governance Decision on Official Telegram Channels - 120
  • Phinge CEO Ranked #1 Globally by Crunchbase for the Last Week, Will Be in Las Vegas Jan. 4-9, the Week of CES to Discuss Netverse & IPO Coming in 2026
  • Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
  • ToneWell Launches AI Wellness Platform with 30-Second Voice-Based Performance Readiness Scan™
  • VIP Vacations Wins Diamon Status with AIC Hotel Group
  • Eagles LB Jihaad Campbell Brings Surprise Visit for Together We Dance Foundation
  • Stoxtel Introduces High-Throughput "Matrix" Engine to Address Mexico's Crypto Trading Volatility
  • Deimler Chiropractic Announces Expansion
  • Althea Gibson Honored as Final Release in U.S. Mint's American Women Quarters Program

Similar on PennZone

  • VSee Health (N A S D A Q: VSEE) Secures $6.0M At-Market Investment, Accelerates Expansion as Revenues Surge
  • High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
  • OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
  • FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
  • Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • $750 Million Market on Track to $3.35 Billion by 2034: $NRXP Launches First-in-Florida "One Day" Depression Treatment in Partnership with Ampa Health
  • $750 Million Market Set to Soar to $3.35 Billion by 2034 as Florida Launches First-in-Nation One-Day: NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP
  • U.S. Entrepreneur Anjo De Heus Builds Innovation Bridge Between America and the Gulf
  • Global Innovators Take the Stage at the WorldUpstart Accelerator Showcase in Philadelphia
  • Phinge's Netverse to Redefine Clinical Trial Safety and Data Integrity with Netverse Patented, Hardware-Verified Platform
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us